<sup>18</sup>F-FDG分子符合成像非肿瘤性摄取与对策

李林法

¹⁸F-FDG分子符合成像非肿瘤性摄取与对策

李林法

文章导航 > 国际放射医学核医学杂志 > 2002, 26 > 5: (205-209)

引用本文:

Citation:

¹⁸F-FDG分子符合成像非肿瘤性摄取与对策

李林法

310003 浙江, 浙江大学医学院附属第一医院核医学科

作者简介: 李林法(1965-),男,浙江杭州桐庐人,副主任医师,硕士,主要从事核素肿瘤显像和治疗研究。;

中图分类号: R817.4

Nonmalignant accumulations and its decision of ¹⁸F-FDG molecular coincidence imaging

LI Lin-fa

Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Hangzhou 310003, China
CLC number: R817.4

摘要: ¹⁸F-FDG显像可以提供肿瘤细胞生物特性信息,且大多数肿瘤具有靶/非靶高比率的特性,目前已有效地应用于全身各种肿瘤。但是,除肿瘤外,正常组织及一些良性病变也可摄取¹⁸F-FDG,这些非肿瘤摄取常可造成假阳性或者掩盖恶性肿瘤灶。通过阐述各种非肿瘤性摄取,包括生理性、良性、炎症性摄取的特点以及鉴别点,图像融合、双时相显像应用到非肿瘤性摄取的鉴别,认为同机图像融合是鉴别肿瘤性摄取与生理性摄取首选方法。
- ¹⁸F-氟代脱氧葡萄糖 /
- 生理性摄取 /
- 良性病变 /
- 肿瘤 /
- 鉴别诊断
Abstract: ¹⁸FF-FDG imaging can provide information about the biologic characteristics of malignant cells,and has high target-to-nontarget ratios in most common neoplasms,recently has been successfully used in various neoplasms throughout the body.However ¹⁸F-FDG is a non specific tracer,and it has been found to accumulate at sites of normal tissue and some benign pathologic.This uptake of nonmalignant tissue may be misinterpreted as a false positive result or mask a nearby malignant lesion.We describe various nonmalignant uptake's characteristic and differential including physiologic,benign,infection and inflammation,image fusion,dual time point imaging be applied to distinguish nonmalignant accumulations.Con sider the combined imaging fusion is the first optimal modality in distinguish m alignant accumulations from physiologic.
- 2-¹⁸F-fluoro-2-deoxy-D-glucose /
- physiological accumulations /
- benign pathologic /
- neoplasms /
- differential
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Shreve PD, Anzai Y, Wahl RL. Pitfall in oncologic diagnosis with FDG PET imaging:physiologic and benign variants[J].Radiographics, 1999, 19(1):61-77.
[2]	Brigid GA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography:normal variations, pitfalls, and technical considerations[J]. Am J Roentgenol, 1997,169:1675-1680.
[3]	Miraldi F, Vesselle H, Faulhaber PF, et al. Elimination of artifactual accumulation of FDO in PET imaging of colorectal cancer[J]. Clin Nucl Med, 1998, 23:3-7.
[4]	Conti PS, Durshi JM, Singer PA, et ah Incidence of thyroid gland uptake of F-18 FDG in cancer patients[J]. Radiology,1997, 205:220.
[5]	Bar-Shalom R. Muscle uptake of 18-fluorine fluoro deoxyglucose[J]. Semin Nucl Med, 2000, 30(4):306-309.
[6]	Engel H, Steinert H, Buck A, et al. Whole-body PET:Physiological and artifactual fluorodeoxyglucose accumulations[J]. J Nucl Med, 1996, 37:441-446.
[7]	Mossberg KA, Mommession JI, Taegtmeyer H. Skeletal muscle glucose uptake during short-term contractile activity in vivo:effect of prior contractions[J]. Metabolism, 1993, 42:1609-1616.
[8]	Kostakoglu L, Wong JCH, Barrington SF, et al. Speech-related visualization of laryngeal muscles with fluorine-18-FDG[J]. J Nucl Med, 1996, 37:1771-1773.
[9]	Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine 18-FDG:effect on oral diazepam[J]. J Nucl Med, 1996, 37:1127-1129.
[10]	赵军.¹⁸F-FDG PET诊断肿瘤应考虑的几个问题[J].国外医学·放射医学核医学分册,1999,23(6):241-245.
[11]	Sugawara Y, Fisher SJ, Zasadny KR, et al. Pre-clinic and clinic studies of bone marrow uptake of fluorine-18-fluo-rodeoxyglucose with or without granulocyte colony-stimulating factor during chemotheraphy[J]. J Clin Oncol, 1998,16:173-180.
[12]	Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum:mormal anatomy, variants,pathologic conditions, and strategies to avoid diagnostic pitfalls[J]. Radiographics, 1998, 18:805-823.
[13]	Kosuda S, Fisher S, Kison PV, et al. Uptake of 2-deoxy-2-¹⁸F-fluoro-D-glucose in normal testis:retrospective PET study and animal experiment[J]. Ann Nucl Med, 1997, 11:195-199.
[14]	Chander S, Meltzer CC, Mccook BM. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography[J]. Clin Nucl Med, 2002, 27(1), 22-24.
[15]	Meyer M, Gast T, Raja S, et al. Increased F-18 FDG accumulation in an acute fracture[J]. Clin Nucl Med, 1994, 19:13-14.
[16]	Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sacoidosis[J]. J Nucl Med,1994, 35:1647-1649.
[17]	Strauss LG. Fluorine-18-deoxyglucose and false-positive results:a major problem in the diagnostics of oncological patients[J]. Eur J Nucl Med, 1996, 23:1409-1415.
[18]	Kim SK, Chung JK, Kim BT, et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET[J]. Radiographics, 1999, 19:61-77.
[19]	Yun MJ, Jang SY, Cucchiara A, et al. ¹⁸F-FDG uptake in the large arteries:Acorrelation study with the atherogenic risk factors[J]. Semin Nucl Med, 2002, 32(1):70-76.
[20]	Paul G, Kluetz BS, Carolyn CM, et al. Combined PET/CT imaging in oncology impact on patient management[J]. Clin Positronimag, 2000, 3(6):223-230.
[21]	Inagaki H, Kato T, Tadokoro M, et al. Interactive fusion of three-dimensional imagines of upper abdominal CT and FDG PET with no body surface markers[J]. Radiat Med, 1999, 17:155-163.
[22]	Zhuang HM, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation[J]. Semin Nucl Med, 2002, 32(1):47-59.
[23]	Mamede M, Saga T, Ishimori T, et al. Differential uptake of F-18-FDG in experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of steroid pretreatment on tumor uptake[J]. J Nucl Med, 2001,42:1172.
[24]	Zhuang HM, Pourdehnad M, Lambright ES, et al. Dual time point ¹⁸F-FDG PET imaging for differentiating malignant from inflammatory processes[J]. J Nucl Med, 2001, 42(9):1412-1417.
[25]	Matties A, Hickeson M, Cuchiara A, et al. Dual time point ¹⁸F-FDG PET for the evaluation of puimonary nodules[J]. J Nucl Med, 2002, 43(7):871-875.
[26]	Nakamoto Y, Higashi T, Sakahara H, et al. Delayed FDGPET scan for the differentiation between malignant and benign lesions[J]. J Nucl Med, 1999, 40:247.
[27]	Herzog HR, Borner AR, Weckesser M, et al. Delayed scan time for FDG PET in breast cancer[J]. J Nucl Med, 1999,40:140.
[28]	Ishizu K, Nakamura S, Shiozaki T, et al. Increasing rate of FDG uptake from early to delayed PET images in lung tumors[J]. J Nucl Med, 2000, 41:76.

[1]	吴湖炳 . ¹⁸F-氟代脱氧葡萄糖PET-CT在头颈部肿瘤中的应用价值. 国际放射医学核医学杂志, 2005, 29(5): 205-209.
[2]	尹立杰 . 双时相¹⁸F-FDG PET在肿瘤良恶性鉴别诊断中的应用. 国际放射医学核医学杂志, 2004, 28(2): 53-56.
[3]	刘建军 , 黄钢 . ¹⁸F-氟代脱氧葡萄糖PET和PET-CT在转移性骨肿瘤中的应用研究. 国际放射医学核医学杂志, 2005, 29(5): 213-216.
[4]	蔡莉 , 李彦生 . 氟代脱氧葡萄糖与氨基酸PET在脑肿瘤中的对比研究. 国际放射医学核医学杂志, 2005, 29(1): 10-14.
[5]	郭睿 , 晋建华 , 任媛 , 李思进 , 李险峰 , 张晓娟 . ^99mTc-枸橼酸盐显像鉴别骨转移癌与良性退行性骨病变. 国际放射医学核医学杂志, 2008, 32(3): 162-164.
[6]	王俊起 . ¹⁸F-FDG PET/CT的特点及其在肿瘤诊断中的应用. 国际放射医学核医学杂志, 2004, 28(2): 49-53.
[7]	华逢春 , 管一晖 , 赵军 . ¹⁸F-氟代脱氧葡萄糖PET及PET-CT在淋巴瘤中的临床应用. 国际放射医学核医学杂志, 2005, 29(5): 216-219,226.
[8]	孙琳 , 高再荣 , 张永学 . ¹⁸F-氟代脱氧葡萄糖PET-CT用于恶性肿瘤治疗疗效评估与监测. 国际放射医学核医学杂志, 2006, 30(6): 328-331.
[9]	吕慧清 , 张中民 , 吕仲虹 . ¹⁸F-氟代脱氧葡萄糖PET在恶性肿瘤适形放射治疗中的价值. 国际放射医学核医学杂志, 2006, 30(6): 335-337.
[10]	袁志斌 . 正电子肿瘤阳性显像剂¹⁸F-AMT. 国际放射医学核医学杂志, 2002, 26(5): 193-195.

点击查看大图

计量

文章访问数: 1132
HTML全文浏览量: 202
PDF下载量: 2

¹⁸F-FDG分子符合成像非肿瘤性摄取与对策

李林法

作者简介:李林法(1965-),男,浙江杭州桐庐人,副主任医师,硕士,主要从事核素肿瘤显像和治疗研究。

310003 浙江, 浙江大学医学院附属第一医院核医学科

收稿日期: 2002-08-17

关键词:

摘要: ¹⁸F-FDG显像可以提供肿瘤细胞生物特性信息,且大多数肿瘤具有靶/非靶高比率的特性,目前已有效地应用于全身各种肿瘤。但是,除肿瘤外,正常组织及一些良性病变也可摄取¹⁸F-FDG,这些非肿瘤摄取常可造成假阳性或者掩盖恶性肿瘤灶。通过阐述各种非肿瘤性摄取,包括生理性、良性、炎症性摄取的特点以及鉴别点,图像融合、双时相显像应用到非肿瘤性摄取的鉴别,认为同机图像融合是鉴别肿瘤性摄取与生理性摄取首选方法。

English Abstract

全文HTML

参考文献 (28)

下载: 全尺寸图片幻灯片

返回文章

用微信扫码二维码

分享至好友和朋友圈

18F-FDG分子符合成像非肿瘤性摄取与对策

作者简介: 李林法(1965-),男,浙江杭州桐庐人,副主任医师,硕士,主要从事核素肿瘤显像和治疗研究。;

Nonmalignant accumulations and its decision of 18F-FDG molecular coincidence imaging

计量

出版历程

18F-FDG分子符合成像非肿瘤性摄取与对策

作者简介:李林法(1965-),男,浙江杭州桐庐人,副主任医师,硕士,主要从事核素肿瘤显像和治疗研究。

English Abstract

Nonmalignant accumulations and its decision of 18F-FDG molecular coincidence imaging

全文HTML

目录

¹⁸F-FDG分子符合成像非肿瘤性摄取与对策

Nonmalignant accumulations and its decision of ¹⁸F-FDG molecular coincidence imaging

¹⁸F-FDG分子符合成像非肿瘤性摄取与对策

Nonmalignant accumulations and its decision of ¹⁸F-FDG molecular coincidence imaging